^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    WU-NK-101

    i
    Associations
    News

    Trials

    Company:
    HCW Biologics, Wugen
    Drug class:
    NK cell stimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Phase 1b Study of WU-NK-101 in Combination With Cetuximab (NCT05674526)
    Phase 1
    Wugen, Inc.
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    05/21/2024
    Primary completion :
    09/30/2025
    Completion :
    06/01/2026
    EGFR • BRAF
    |
    BRAF V600E • BRAF V600 • EGFR expression • RAS mutation
    |
    Erbitux (cetuximab) • WU-NK-101
    A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) (WUN101-01) (NCT05470140)
    Phase 1
    Wugen, Inc.
    Recruiting
    Last update posted :
    09/07/2023
    Initiation :
    07/01/2023
    Primary completion :
    04/30/2024
    Completion :
    12/31/2025
    BCL2
    |
    WU-NK-101